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Among human cancers, adenocarcinomas of the lung, breast,
prostate, colon, and pancreas represent the most common
causes of cancer death in Western societies (Jemal et al.,
2003). Over the past decade, mouse models of human malig-
nancy have contributed significantly to our understanding of
many of these human tumors. Mouse models have been
employed to evaluate novel strategies for early detection,
chemoprevention, and treatment, and classical mouse genetics
have successfully identified modifier loci contributing to the risk
of tumor initiation and/or progression. For example, multiple
strategies for chemoprevention of intestinal polyposis have
been evaluated in the min/APC model (Jacoby et al., 
1996; Roberts et al., 2002; Torrance et al., 2000), and auro-
ra2/Stk6/STK 15 has been shown to be an important modifier of
tumor multiplicity in a murine skin tumor model (Ewart-Toland et
al., 2003). While fundamental differences in biology suggest the
need for caution in equating mouse tumors with their human
counterparts (Rangarajan and Weinberg, 2003; Van Dyke and
Jacks, 2002), mouse models of malignancy nevertheless repre-
sent an important source of insight regarding human neoplasia.
For many human tumors, successful mouse modeling has
been facilitated either by the availability of appropriate cell type-
specific promoter elements for transgene targeting and condi-
tional gene deletion (Hutchinson and Muller, 2000; Kasper et
al., 1998), by an epithelium accessible and susceptible to chem-
ical carcinogenesis (Bolt et al., 2000; Saran et al., 2000), or by
the identification of heritable tumor predisposition following
chemical mutagenesis (Su et al., 1992; Moser et al., 1992). For
other tissues, significant rates of spontaneous or viral-mediated
tumorigenesis have also provided effective mouse models
(Hook et al., 2000; Malkinson, 2001). In stark contrast to the
successful murine modeling of most common human tumors,
the generation of appropriate mouse models of pancreatic can-
cer has remained an area of significant frustration. Combined
with this frustration is a real sense of urgency. Pancreatic can-
cer is an almost uniformly fatal disease, accounting for 30,000
cancer deaths each year in the United States (Jemal et al.,
2003). Among the five most common causes of cancer death
listed above, pancreatic cancer is also the least accessible, with
the retroperitoneal location of the pancreas rendering this tis-
sue largely unavailable for routine tissue sampling or radi-
ographic/endoscopic screening. As such, initiating events in
human pancreatic cancer have been difficult to discern, and the
potential benefits of a mouse model loom large.
Ironically, the mouse pancreas was one of the very first
organs in which tissue-specific transgene expression was
accomplished, and among the first tissues in which transgenic
tumor induction was achieved (Ornitz et al., 1985, 1987; Quaife
et al., 1987; Swift et al., 1984). These events were facilitated by
the identification of tissue-specific promoter/enhancer elements
in the rat elastase I locus. These elements predominantly target
pancreatic acinar cells and produced acinar cell neoplasms
when coupled to either activated H-ras or SV40 T-antigen. In
contrast, expression of a c-myc transgene driven by the same
promoter produced mixed acinar/ductal neoplasms (Sandgren
et al., 1991), raising fascinating questions regarding the ability
of specific oncogenes to either selectively initiate tumorigenesis
in specific cell populations or to drive tumor differentiation in a
directed manner. However, the generation of mouse models
producing classic pancreatic ductal adenocarcinoma, the pre-
dominant form of human pancreatic cancer, was not achieved in
these early studies.
Subsequent to these reports, the decade of the 1990s wit-
nessed a dramatic expansion of knowledge in two important
areas related to pancreatic tumorigenesis. First, the genetic
basis of pancreatic ductal adenocarcinoma was revealed, with
activation of KRAS and inactivation of the p16INK4a, p53, and
SMAD4 tumor suppressor genes identified as characteristic
features of invasive pancreatic cancer (Hruban et al., 2001b).
Second, consensus was reached regarding the role of pancre-
atic intraepithelial neoplasia (PanIN) as a direct noninvasive
neoplastic precursor to human pancreatic cancer (Figure 1;
Hruban et al., 1999, 2001a).The identification of PanIN as a rel-
evant precursor lesion further allowed the ordering of character-
istic genetic events in a step-wise carcinogenesis paradigm, in
which KRAS mutation and telomere shortening were character-
ized as early events, loss of p16INK4a as an intermediate
event, and loss of p53 and SMAD4 as late events occurring in
PanIN lesions of increasing severity (Edlund, 1999; Maitra et al.,
2003; van Heek et al., 2002;Yeo et al., 2002).
Concomitant with these advances in the understanding of
human pancreatic cancer, significant progress was made in
pancreatic developmental biology, with the identification of mul-
tiple transcription factors and signaling pathways required for
normal foregut patterning, branching morphogenesis, and
establishment of endocrine and exocrine cell lineages (Ahlgren
et al., 1996; Edlund, 1999; Kim and MacDonald, 2002). Among
these factors, the homeodomain protein Pdx1 and the basic
helix-loop-helix protein Ptf1-p48 were implicated as critical reg-
ulators of early pancreatic development, with targeted deletion
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of either of these genes resulting in severely aborted pancreatic
morphogenesis and a paucity of differentiated cell types
(Ahlgren et al., 1996; Kawaguchi et al., 2002; Krapp et al., 1998;
Offield et al., 1996). More recent lineage tracing studies and sin-
gle cell expression profiling have demonstrated that the vast
majority of differentiated cell types are generated from a com-
mon endocrine/exocrine precursor pool expressing both Pdx1
and Ptf1-p48 (Chiang and Melton, 2003; Gu et al., 2003;
Kawaguchi et al., 2002). Additional studies have defined specif-
ic roles for the Hedgehog, EGF, and Notch signaling pathways
in regulating normal pancreatic development in the mouse.
Among these, soluble Hedgehog signals appear to play a criti-
cal role in foregut patterning, acting to restrict pancreatic devel-
opment to nascent dorsal and ventral buds, and promoting gut
and liver differentiation programs in adjacent nonpancreatic
endoderm (Apelqvist et al., 1997; Deutsch et al., 2001; Hebrok
et al., 2000).Within the pancreatic buds, EGF signaling appears
to drive proliferation of undifferentiated precursor cells (Cras-
Meneur et al., 2001), while Notch acts to prevent both
endocrine and exocrine differentiation (Apelqvist et al., 1999;
Hald et al., 2003; Jensen et al., 2000), effectively preserving an
undifferentiated precursor pool.
Against this backdrop of advances in pancreatic cancer
molecular genetics, consensus regarding PanIN precursors,
and identification of transcription factors and signaling path-
ways regulating normal pancreatic development, it might be
expected that progress on mouse models of pancreatic cancer
would finally be made. A series of recent reports validates this
expectation. After years of lagging behind, mouse models of
pancreatic cancer can now be said to have equaled, and in cer-
tain respects surpassed, their counterparts in other tissues.
Specifically, a recent report by David Tuveson and col-
leagues at the University of Pennsylvania (Hingorani et al., 2003)
reports the generation of progressive PanIN lesions and low-fre-
quency progression to invasive and metastatic adenocarcinoma
following activation of oncogenic KRAS in mouse pancreas. In
this report, mice expressing a Cre-activated KRASG12D allele
inserted into the endogenous KRAS locus were crossed with
mice expressing Cre recombinase in pancreatic tissue, either by
virtue of a Pdx1 promoter-driven transgene or by Cre knockin at
the Ptf1-p48 locus. Prior lineage studies suggest that both of
these lines express Cre in a common endocrine/exocrine pre-
cursor cell during development, while expression in adults is
retained in mature islet cells in the case of Pdx1-Cre transgenics
and in mature acinar cells in the case of the Ptf1-p48+/Cre knockin
(Gu et al., 2003; Kawaguchi et al., 2002).
Notably, both the islet and acinar compartments in mice
expressing Pdx1-Cre- or Ptf1-p48+/Cre-activated KRASG12D
appeared histologically normal, at least prior to the onset of pro-
gressive fibrosis. Instead, activation of oncogenic KRAS in
either Cre line resulted in progressive intraductal lesions reca-
pitulating multiple aspects of human PanIN. Specifically, the
normal cuboidal epithelium of small interlobular ducts was con-
verted to a columnar morphology, with minimal involvement of
larger ducts.These changes were apparent as early as 2 weeks
postpartum. Over the course of several months, these early
PanIN lesions were replaced by lesions of progressive architec-
tural and cytologic abnormality, characterized by the develop-
ment of papillary or micropapillary lesions, loss of cell polarity,
and increasing nuclear atypia. By demonstrating this progres-
sion in the mouse, these studies have provided confirmation of
the PanIN progression model initially proposed in human pan-
creas, which has by necessity been generated largely from
examination of static specimens without the benefit of timed ini-
tiation or serial sampling (Brat et al., 1998; Hruban et al., 1999;
Maitra et al., 2003). PanIN lesions from these mice also demon-
strated evidence of Notch pathway activation, as well as expres-
sion of both cyclooxygenase 2 (COX2) and matrix
metalloproteinase 7 (MMP7). These pathways are typically qui-
escent in normal ductal epithelium, but are commonly active in
human PanIN (Crawford et al., 2002; Maitra et al., 2002;
Miyamoto et al., 2003). In addition, serum from these mice
demonstrated a characteristic proteomic signature, even in the
absence of invasive disease. While it remains uncertain
whether this serum response represents a specific marker of
PanIN as opposed to other consequences of KRAS activation in
pancreatic tissue, the results certainly provide an important
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Figure 1. Histology of normal and neoplastic pancreas
A: Normal mouse pancreas demonstrating preponderant acinar cell mass,
terminal intralobular ductal epithelium (black bracket), centroacinar cells
(arrowheads), and endocrine islet (yellow bracket). Within this complex
epithelial tissue, the location of dedicated epithelial precursor cells is
unknown, and the cell of origin for pancreatic intraepithelial neoplasia is
not yet defined. 
B: Human pancreatic intraepithelial neoplasia (PanIN), demonstrating
columnar epithelium with papillary architecture and surrounding desmo-
plastic stroma. PanIN image courtesy of Dr. Ralph Hruban, Johns Hopkins
University.
CANCER CELL : JANUARY 2004 9
precedent supporting similar efforts to detect pre-invasive
lesions in human pancreas.
While spontaneous invasion and metastasis were observed
at low frequency following activation of oncogenic KRAS in
mouse pancreas, a subsequent report from Ronald DePinho,
Nabeel Bardeesy, and colleagues at the Dana Farber Cancer
Institute of Harvard Medical School demonstrated accelerated
PanIN formation, rapid tumor progression, and fatal metastatic
disease when Pdx1-Cre-activated KRASG12D activation is com-
bined with tissue-specific Ink4a/Arf deficiency (Aguirre et al.,
2003). In this study, mice expressing Pdx1-Cre-activated
KRASG12D developed PanIN lesions and progressive pancreatic
fibrosis, but no evidence of invasive cancer, as assessed up to 30
weeks of age. However, when expressed in the context of com-
bined Cre-mediated excision of loxP-flanked Ink4a/Arf alleles, all
mice succumbed to invasive and metastatic pancreatic cancer
within 11 weeks. Pdx1-Cre;Ink4a/Arflox/lox mice lacking the Cre-
activated KRASG12D transgene failed to develop pancreatic
tumors, specifically implicating a role for oncogenic KRAS in
tumor initiation and a role for Ink4a/Arf in tumor progression.
Additional molecular changes observed in these aggressive
tumors included amplification of the mutant KRAS allele and
evolving expression of EGFR and HER2/NEU. In contrast, no evi-
dence of acquired mutation in SMAD4 or p53 was observed, sug-
gesting that (in the mouse) these tumor suppressors are not rate
limiting for generation of invasive and metastatic pancreatic can-
cer, at least in the presence of combined Ink4a/Arf deficiency.
Combined with other recent papers evaluating oncogenic
KRAS targeting to either mature acinar cells using the elastase
1 promoter (Grippo et al., 2003) or mature ductal epithelium
using the cytokeratin 19 promoter (Brembeck et al., 2003),
these studies raise additional fascinating questions regarding
the true cell of origin for pancreatic ductal adenocarcinoma.
While these studies are unable to provide definitive resolution of
this question, the fact remains that KRAS targeting to acinar
cells appears to result in acinar or mixed acinar/ductal tumors,
while targeting mature ductal epithelium results in periductal
inflammation, without characteristic PanIN formation. Together
with the observation of normal islet and acinar cell populations
in mice with oncogenic KRAS activated by either the Pdx1-Cre
transgene or the Ptf1-p48+/Cre knockin (Hingorani et al.), these
observations suggest that PanIN lesions may not arise from dif-
ferentiated exocrine or endocrine cell types, but rather from
undifferentiated precursor cells targeted by Pdx1 and/or Ptf1-
p48 regulatory elements.
Further insights regarding this issue are provided by a
recent study reported by Harold Varmus and collegues from the
Memorial Sloan-Kettering Cancer Center (Lewis et al., 2003).
Using transgenic mice expressing TVA, the receptor for avian
leukosis sarcoma virus subgroup A (ALSV-A), under control 
of elastase 1 promoter elements, these investigators used 
ALSV-A-based RCAS vectors to selectively deliver either poly-
oma virus middle T-antigen (PyMT) or c-myc to elastase-
expressing cells in mouse pancreas. Although the genetic
alterations introduced in these mice are not typically observed in
human pancreatic cancer, this novel method for tissue-specific
gene delivery appears to carry multiple advantages, including
the ability to introduce a variety of different oncogenes to specif-
ic target cells using a single transgenic line, stochastic oncogene
activation in a limited number of cells, and the benefit of temporal
control based on timed intraperitoneal delivery of the viral vector.
In this study, expression of the TVA transgene appeared to
be limited to elastase-expressing acinar cells, although expres-
sion in a low-frequency nonacinar precursor cell cannot be
excluded. Delivery of PyMT to this population resulted in a vari-
ety of tumor types showing varying degrees of either acinar or
ductal differentiation, as well as occasional cystadenocarcino-
mas. A subset of ductal lesions displayed features of PanIN.
Both acinar and ductal tumors expressed Pdx1 and demonstrat-
ed either uniform or focal expression of synaptophysin, suggest-
ing possible involvement of a multipotent precursor cell. As in
the case of KRASG12D-induced tumors, tumor progression
appeared to be accelerated in the absence of Ink4a/Arf. In con-
trast, delivery of c-myc to elastase-expressing cells resulted in
tumor formation only in the context of Ink4a/Arf deficiency, and
all tumors demonstrated an endocrine pattern of differentiation.
These tumors closely resembled well-differentiated human pan-
creatic endocrine tumors, in which enhanced c-myc expression
is often observed.
In addition to providing exciting new models with which to
conduct preclinical studies, these reports highlight a number of
considerations likely to inform future work in the field. First, the
cumulative results of these and other studies suggest that differ-
entiated pancreatic cell types may be relatively resistant to
KRAS-driven generation of PanIN lesions, and may not repre-
sent the proximate cell of origin for classical pancreatic ductal
adenocarcinoma. Instead, these tumors may be derived from
either undifferentiated precursor cells or dedifferentiated deriva-
tives of mature cell types, reflecting a significant capacity for
plasticity among differentiated exocrine and endocrine cells
(Meszoely et al., 2001). Second, advances in the field of pan-
creatic developmental biology will likely continue to be informa-
tive with respect to ongoing refinement and characterization of
these and other mouse models. In addition to adding to the
reagent toolbox, improved understanding of pancreatic devel-
opmental biology has stimulated identification of the Hedgehog
and Notch signaling pathways as characteristic features of both
PanIN and invasive human pancreatic cancer (Berman et al.,
2003; Miyamoto et al., 2003; Thayer et al., 2003). Together with
the established ability of EGF receptor signaling to regulate
pancreatic epithelial differentiation and initiate pancreatic
tumorigenesis (Wagner et al., 2001, 2002), these pathways not
only represent intriguing targets for chemoprevention but may
also provide a molecular handle for identification of putative pre-
cursor cells responsible for PanIN initiation. While it is clear that
the study of pancreatic development has had significant impact
on our view of pancreatic neoplasia, we should also expect that
these new tumor models may in turn provide much needed
enlightenment regarding the presence, location, and identity of
dedicated precursor cells in adult and embryonic pancreas.
So where do we stand? For the first time, we have a model
of pre-invasive pancreatic epithelial neoplasia that faithfully
recapitulates multiple aspects of the human disease.The model
provides a unique opportunity to evaluate strategies for early
detection of noninvasive disease, perhaps taking advantage of
global or specific changes in serum protein profiles, as suggest-
ed by Hingorani et al. (2003). In addition, the mouse PanIN
model now allows formal evaluation of novel chemoprevention
strategies, with pharmacologic inhibiton of COX2, MMP7, EGF,
Notch, and Hedgehog all providing exciting possibilities.
Moreover, the combination of targeted KRASG12D activation and
Ink4a/Arf deletion reported by Aguirre et al. (2003) provides the
ability to study the impact of various therapeutic interventions
on invasive and metastatic disease developing along a canoni-
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cal PanIN-to-carcinoma sequence. Combined with the recent
insights regarding Notch and Hedgehog signaling alluded to
above, the past few months have witnessed a period of remark-
able progress in modeling and understanding this disease.
Caution certainly remains necessary in assuming that fur-
ther information generated by these models will be directly
translatable to human pancreatic cancer. However, at the very
least, these new models should facilitate ongoing efforts to clar-
ify basic biologic questions regarding pancreatic ductal adeno-
carcinoma and its noninvasive precursors: what is the cell of
origin? How do stromal factors influence pathogenesis? What
are the effects of epithelial injury on relevant precursor cells, as
well as on tumor initiation and/or progression? Are nonmuta-
tional changes in EGF, Notch, and Hedgehog signaling required
to initiate, modify, or enforce the phenotypic response to onco-
genic KRAS, or do these represent downstream sequelae?
How do commonly observed metaplastic changes in epithelial
differentiation contribute to PanIN initiation?
In order to productively address these questions, it will be
critical to recognize that no single mouse model is likely to mir-
ror the full spectrum of human pancreatic ductal adenocarcino-
ma and its precursors. While recent efforts have emphasized
the role of PanIN as a direct precursor for invasive pancreatic
cancer, our view of the human disease remains largely static. It
is likely that not all pancreatic ductal adenocarcinoma is gener-
ated by way of a canonical PanIN sequence, and that multiple
pathways and multiple trajectories exist by which transformed
pancreatic epithelial cells may arrive at an apparently common
phenotype. It is therefore important to recognize that each of the
models in our collective mouse colony, even those not directly
mimicking human PanIN, may provide important insights
regarding underlying biology.
This may also be true for studies of experimental therapeu-
tics. For evaluation of novel therapies targeting specific molecu-
lar defects, molecular mimicry of human tumors may prove to be
more important than histologic mimicry (Van Dyke and Jacks,
2002). Mouse models displaying high degrees of molecular
homology with their human counterparts (Wagner et al., 2001)
may therefore remain highly informative with respect to preclini-
cal studies, even if differences exist with respect to histologic
progression.
In association with the recent proliferation of available
mouse models, it will also be critical to develop consensus
regarding the spectrum of neoplastic phenotypes observed in
mouse pancreas and to apply stringent criteria and a well-
defined nomenclature when relating mouse phenotypes to
human disease.The successful development of such criteria for
human PanIN has required extensive efforts to achieve consen-
sus (Hruban et al., 2001a). Only a short time ago, there might
have been little enthusiasm for a proposed consensus confer-
ence on mouse pancreatic cancer pathology, based on a pauci-
ty of material to review. Fortunately, such a conference now
appears both timely and necessary.
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